Microsoft's cloud and productivity services, including Azure and Microsoft 365, experienced a significant disruption ...
Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback